{"id":"W4236840402","doi":"10.3410/f.734560442.793577561","title":"Faculty Opinions recommendation of Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Brentuximab vedotin; CD30; Medicine; Oncology; Chemotherapy; Internal medicine; Lymphoma; Peripheral T-cell lymphoma; Peripheral; Not Otherwise Specified; Immunology; T cell; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00434218,0.001252024,0.002112316,0.0007563305,0.0005772964,0.002203726,0.002698717,0.002592319,0.1176951],"category_scores_gemma":[0.0223082,0.000727543,0.003384502,0.001692376,0.0003279017,0.001331432,0.001321734,0.002158079,0.02993533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001603953,"about_ca_system_score_gemma":0.003923931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005985707,"about_ca_topic_score_gemma":0.01997847,"domain_scores_codex":[0.9978265,0.001028051,0.0003155194,0.0003262287,0.0003463667,0.0001572534],"domain_scores_gemma":[0.9928532,0.002436786,0.001629916,0.00106286,0.00124072,0.0007764828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.009941773,0.0001179989,0.001745197,0.008111008,0.001516839,0.00002149941,0.0000170061,0.0002990589,0.000220686,0.0005166329,0.9658443,0.01164799],"study_design_scores_gemma":[0.1455097,0.0009428699,0.02166071,0.005835683,0.005173991,0.0002011412,0.00006765407,0.001481845,0.0008522471,0.004125665,0.8140134,0.0001349676],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"dataset","genre_gemma":"dataset","genre_scores_codex":[0.0007075161,0.000803294,0.0002206256,0.001184924,0.0001444569,0.0005413265,0.9938803,0.0002045254,0.002313061],"genre_scores_gemma":[0.009022094,0.001158238,0.002299493,0.002614312,0.0001920618,0.005508068,0.9708903,0.0002167523,0.008098657],"genre_candidate":"dataset","genre_consensus":"dataset","teacher_disagreement_score":0.1176951,"threshold_uncertainty_score":0.3937293,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04131373926731945,"score_gpt":0.3787348686452047,"score_spread":0.3374211293778852,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}